agilon Swings to $35M Q3 Profit, Lifts 2026 Adjusted EBITDA Guidance to $145-$155M
AGL has more than doubled off its 52-week low of $7.48.
Summary
agilon health swung to $35 million of Q3 2026 net income from a $110 million loss and raised full-year Adjusted EBITDA guidance to $145-$155 million from $75-$95 million, even as platform membership fell 8%.
Key Events · Earnings and Guidance · AGL
-
Q3 Swing to $35M Net Income
Net income was $35 million in Q3 2026 versus a net loss of $110 million in Q3 2025; Adjusted EBITDA was $64 million versus negative $91 million.
-
2026 Adjusted EBITDA Guidance Raised
Full-year 2026 Adjusted EBITDA guidance rose to $145-$155 million from $75-$95 million, and revenue guidance to $5.87-$5.89 billion from $5.775-$5.86 billion.
-
Medical Cost Ratio Improves Sharply
The medical services expense ratio fell to 88.5% in Q3 2026 from 104.0% a year earlier, helped by favorable claims development in the first half of 2026.
-
Membership Still Contracting
Total members on the platform fell 8% to 566,000 as of September 30, 2026, including 454,000 Medicare Advantage members, reflecting disciplined contracting and previously disclosed market exits.
Analysis · AGL · Industrial Applications And Services
The headline number is a $35 million net profit in Q3 2026, a sharp reversal from a $110 million loss a year earlier, with Adjusted EBITDA at $64 million versus negative $91 million. More consequential is the full-year outlook: Adjusted EBITDA guidance was raised to $145-$155 million from $75-$95 million, and revenue guidance to $5.87-$5.89 billion from $5.775-$5.86 billion. The medical services expense ratio fell to 88.5% from 104.0%, meaning the company is finally keeping more of each premium dollar after years of losses. Membership, however, is still shrinking — total members on the platform fell 8% to 566,000 — so the profit is coming from cost discipline and favorable claims development rather than growth. On the balance sheet, $312 million of cash and marketable securities against $32 million of debt leaves no near-term funding pressure.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AGL was trading at $100.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $7.48 to $133.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.